PIM
TERN

Platinum Investment Management’s Terns Pharmaceuticals TERN Stock Holding History

Platinum Investment Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.84M Hold
110,734
– – 1.47% 18
2025
Q4 		$4.47M Sell
110,734
-14,422
-12% -$333K 1.03% 36
2025
Q3 		$940K Buy
+125,156
New +$799K 0.06% 84

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Platinum Investment Management's TERN Position: Q1 2026 in Review

Platinum Investment Management held its Terns Pharmaceuticals (TERN) position steady in Q1 2026 at 110,734 shares worth $5.84M. The position accounts for 1.47% of the portfolio, ranked #18.

Platinum Investment Management first reported a position in TERN in Q3 2025 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Platinum Investment Management held 110,734 shares of Terns Pharmaceuticals worth $5.84M as of Q1 2026.
  • Platinum Investment Management left its Terns Pharmaceuticals share count unchanged in Q1 2026.
  • Terns Pharmaceuticals made up 1.47% of Platinum Investment Management's portfolio in Q1 2026, its #18 holding.
  • Platinum Investment Management first reported a position in Terns Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.